Alzheimer Disease

As an investigational monoclonal antibody, posdinemab targets the mid-domain of AD-specific phosphorylated tau.

These inequalities, which can include socioeconomic disparities, show neurological changes associated with aging and dementia.

New mechanisms of action are proving more effective than ever, offering slowed progression.

Policies that focus on earlier diagnosis, treatment initiation, and expanded access to treatment can further improve treatment and health equity impacts.

High fluctuations (in the top 25%) in total cholesterol were associated with a 60% increase in dementia and a 23% increase in cognitive decline.

Use of antitherapeutic medication prescribed for herpes zoster related to lower risk of subsequent dementia.

There has never been such widespread and popularized use of compounded products due to shortages. Will consumers rise up with pitchforks if the party is shut down?

For up to 6 years, cognitive remediation and transcranial direct current stimulation slowed cognitive decline associated with major depressive disorder in remission and mild cognitive impairment.

Disruptions in the salience network function are shown to influence the severity of mild behavioral impairment (MBI) symptoms.

Poor sleep quality is directly related to mortality risk before adjusting for lifestyle or health-related factors, and dementia was noticeably linked to mortality risk in older White males.

The authors note this is the first study to assess cerebrovascular endothelial extracellular vesicles within a cognitive condition.

Using the term "pseudodementia" contributes to the mismanagement and mistreatment of the disease.

ALZ-801 has now progressed to the phase 3 APOLLOE4 study, designed to evaluate efficacy, safety, and biomarker and imaging effects.

Despite questions and controversy around some clinical research, new understandings of the pathophysiology of the disease are pushing treatments forward.

The study may serve as a foundation for future investigation regarding dietary recommendations to support the treatment of Alzheimer disease.

Findings from 2 large datasets suggest hormone therapy may reduce Alzheimer risk, hippocampal atrophy, and cerebrovascular disease.

Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.

Improvements were observed in both the intervention and control group, with those who had self-reported learning difficulties showing the least improvement.

Small adjustments in human pluripotent stem cell cultures and the molecule concentration patterns in the initial 5 days of differentiation are essential to “rescue” the lines.

Periodontitis and AD are both characterized by inflammatory and immunological response by the host.

Study results demonstrated that lecanemab provided sustained benefits over 36 months, such as improved biomarker profiles and slowed cognitive decline compared with placebo.

The findings indicate that zoster vaccine recombinant reduced dementia risk by 17% in an analysis of over 200,000 patients.

Benzgalantamine (Zunveyl; Alpha Cognition) is a cholinesterase inhibitor indicated for the treatment of mild-to-moderate dementia in adults.

The FDA’s designation builds off positive results in a phase 1b/2a clinical trial, showing that the vaccine can effectively target the Tau protein.

Safety and efficacy findings on Lomecel-B will be presented at the upcoming 2024 Alzheimer’s Association International Conference, which will be held July 28 to August 1.

Donanemab-azbt is the first and only amyloid plaque targeting therapy that supports stopping therapy when the plaque is removed.

Anti-amyloid antibody administration decreased plaque volume in clinical trials of patients with early AD, indicating that passive immunotherapies could be a promising treatment for the disease.

The default-mode network method, which was analyzed using functional magnetic resonance imaging scans, was approximately 80% accurate when predicting dementia up to 9 years prior to a diagnosis.

Donanemab was able to significantly slow clinical progression of Alzheimer disease and amyloid and tau pathology at 76 weeks of treatment.